Regulatory expression of lipoxin A4 receptor in physiologically estrus cycle and pathologically endometriosis.
Expression of receptors for prostaglandin (PG) and leukotriene (LT) has been reported to detect in endometrium and smooth muscle of uterus, suggesting involvement of these arachidonic metabolites in endometrial pathology and reproductive biology. Lipoxin (LX), which is produced by lipoxygenases from arachidonic acid, has been characterized as an anti-inflammatory lipid mediator. Biological actions of Lipoxin A4 (LXA4) are mediated through the specific receptor. In order to know roles of LXA4 in female genitalia, expression of LXA4 receptor mRNA was quantified by real-time polymerase chain reaction. Significantly higher expression of the receptor was detected in endometrium and myometrium than ovary in normal rats. Expression of the receptor in endometrium was increased at stage of proestrus cycle under physiological condition. Exogenous administration of progesterone into female rats significantly reduced the expression, while administration of estradiol or pregnant mare serum gonadotropin (PMSG) did not. Both, endometrium in experimental endometriosis induced in rats and the tissues from patients with ectopic endometriosis showed a higher expression of LXA4 receptor compared to the normal tissues. In contrast, expressions of BLT1 and BLT2, receptors for leukotriene B4, did not change in the endometriosis. These observations suggest a possible role of LXA4 and the receptor under physiological estrus cycle and pathological condition as endometriosis.
Motohashi
E
E
Department of Obstetrics and Gynecology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan.
Kawauchi
H
H
Endo
H
H
Kondo
H
H
Kitasato
H
H
Kuramoto
H
H
Majima
M
M
Unno
N
N
Hayashi
I
I
D019326:17-alpha-Hydroxyprogesterone / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004715:Endometriosis / Q000235:genetics*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004958:Estradiol / Q000494:pharmacology; D030762:Estrous Cycle / Q000502:physiology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics*; D006064:Gonadotropins, Equine / Q000494:pharmacology; D006801:Humans; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010053:Ovary / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044067:Receptors, Lipoxin / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012710:Serum Albumin, Bovine / Q000494:pharmacology
D006064:Gonadotropins, Equine; D044067:Receptors, Lipoxin; C482540:lipoxin A(4) receptor, rat; D012710:Serum Albumin, Bovine; D011374:Progesterone; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone